Vanoxerine is a multi-ion channel blocker. For this reason, it was developed as a therapy for atrial fibrillation. However, in Phase III trials, 11.5% of patients developed torsades de pointes. Using MEA and human iPSC-derived cardiomyocytes, it was possible to detect this cardiotoxic liability.
In this poster, we focus on:
- the use of MEA and human iPSC-derived cardiomyocytes to detect vanoxerine arrhythmias
- the time dependent effect of vanoxerine cardiotoxicity
- the ADME properties of vanoxerine which may impact on its cardiotoxic effect
Read our poster to learn more about our research!